However, although a number of the previous studies have investigated the role of GPR40 in hepatic steatosis and inflammation [25–27], the findings are controversial and the role of GPR40 in NAFLD associated with T2DM or MetS has not been well established. This evidence concerns the gene FFAR1 and metabolic dysfunction-associated steatotic liver disease.